{"_meta":{"attribution":"Data aggregated by pdata.world (https://pdata.world) from 8 prediction-market venues; CC BY 4.0; source data © each venue.","canonical_url":"https://pdata.world/events/kalshi/KXSAROGLITAZAR-27","as_of":"2026-10-24T09:10:21.094147Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)\" — 75% as of 2026-10-24 UTC. https://pdata.world/events/kalshi/KXSAROGLITAZAR-27","source_url":"https://kalshi.com/markets/kxsaroglitazar/fda-decision-saroglitazar-by-zydus-therapeutics-in-2026/kxsaroglitazar-27"},"source":"kalshi","id":"KXSAROGLITAZAR-27","ticker":"KXSAROGLITAZAR-27","slug":"KXSAROGLITAZAR-27","title":"FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)","description":null,"image":null,"icon":null,"active":true,"closed":false,"start_date":"2026-06-17T21:30:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":null,"volume":1309.02,"volume_24hr":1.57,"volume_24h_change":null,"normalized_vol_24hr":0.29754838347435,"normalized_volume":13.800240516662598,"liquidity":null,"open_interest":725.85,"categories":["Finance"],"tags":[],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"a full approval or an accelerated approval","top_outcome_probability":0.75,"top_outcome_prob_24h_change":-0.010000000000000009,"top_outcome_volume_24h_change":1.57,"updated_at":"2026-10-24T08:06:38.374305Z","fetched_at":"2026-10-24T08:06:38.374305Z","added_at":"2026-06-17T21:41:00.427380Z","url":"https://kalshi.com/markets/kxsaroglitazar/fda-decision-saroglitazar-by-zydus-therapeutics-in-2026/kxsaroglitazar-27","chart_24h":null,"kind":"live","mutually_exclusive":true,"markets_total":1,"markets":[{"source":"kalshi","id":"KXSAROGLITAZAR-27-Y","event_id":"KXSAROGLITAZAR-27","slug":"KXSAROGLITAZAR-27-Y","question":"What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?","group_item_title":"a full approval or an accelerated approval","description":"If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nSaroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars. Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial. In the EPICS-III trial, it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.","image":null,"icon":null,"outcomes":["Yes","No"],"outcome_prices":[0.75,0.25],"probability":0.75,"spread":0.07999999999999996,"active":true,"closed":false,"start_date":"2026-06-17T21:30:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":"2027-01-01T04:59:00Z","result":null,"volume":1309.02,"volume_24hr":1.57,"prob_24h_change":-0.010000000000000009,"volume_24h_change":1.57,"normalized_vol_24hr":0.3332951068878174,"normalized_volume":16.038429260253906,"liquidity":null,"categories":["Finance"],"countries":["United States"],"updated_at":"2026-10-24T08:06:38.502349Z","fetched_at":"2026-10-24T08:06:38.502349Z","added_at":"2026-06-17T21:41:00.581647Z","url":"https://kalshi.com/markets/kxsaroglitazar/fda-decision-saroglitazar-by-zydus-therapeutics-in-2026/kxsaroglitazar-27","event_title":"FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)","chart_24h":[0.76,0.76,0.75]}]}